Ignite Creation Date:
2024-05-06 @ 9:07 AM
Last Modification Date:
2024-10-26 @ 12:09 PM
Study NCT ID:
NCT02900651
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-20
First Post:
2016-09-02
Brief Title:
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Diffuse Large B-cell Lymphoma |
Keywords:
| Name | View |
|---|---|
| MAK683 DLBCL EED - Embryonic ectoderm development EZH2 - Enhancer of zeste homolog 2 | View |